Browse by author
Lookup NU author(s): Professor James Shaw,
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2021 Steunstichting ESOT. Published by John Wiley & Sons LtdAllogeneic islet transplantation is a standard of care treatment for patients with labile type 1 diabetes in many countries around the world, including Japan, the United Kingdom, Australia, much of continental Europe, and parts of Canada. The United States is now endorsing islet cell treatment for type 1 diabetes, but the FDA has chosen to consider islets as a biologic that requires licensure, making the universal implementation of the procedure in the clinic very challenging and opening the manufacture of islet grafts to private companies. The commercialization of human tissues raises significant legal and ethical issues and ironically leads to a situation where treatments developed as a result of the scientific and economic efforts of academia over several decades become exploited exclusively by for-profit entities.
Author(s): Piemonti L, Andres A, Casey J, de Koning E, Engelse M, Hilbrands R, Johnson P, Keymeulen B, Kerr-Conte J, Korsgren O, Lehmann R, Lundgren T, Maffi P, Pattou F, Saudek F, Shaw J, Scholz H, White S, Berney T
Publication type: Article
Publication status: Published
Journal: Transplant International
Online publication date: 28/05/2021
Acceptance date: 24/05/2021
ISSN (print): 0934-0874
ISSN (electronic): 1432-2277
Publisher: Blackwell Publishing Ltd
PubMed id: 34048106
Altmetrics provided by Altmetric